Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary - Scorecard - MDSpire

Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

  • By

  • Charlotte A. Leseman

  • Alessandro M. Bonomi

  • Job Schuitema

  • Stefano Granieri

  • Margaret Sällberg Chen

  • Ajay V. Maker

  • Zeeshan Ateeb

  • Laura D. Wood

  • Rogier P. Voermans

  • Giovanni Marchegiani

  • Marco Del Chiaro

  • Johannes C. F. Ket

  • Anne Marie Lennon

  • Marc G. Besselink

  • Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group

  • June 26, 2026

  • 0 min

Share

Clinical Scorecard: Evaluating Serum CA19.9 Levels for Identifying High-Grade Dysplasia and Invasive Carcinoma in Individuals with Intraductal Papillary Neoplasms

At a Glance

CategoryDetail
ConditionIntraductal Papillary Mucinous Neoplasm (IPMN)
Key MechanismsSerum CA19.9 levels may indicate progression to high-grade dysplasia (HGD) or invasive carcinoma (IC).
Target PopulationPatients with IPMN undergoing surgical resection.
Care SettingClinical decision-making in the context of pancreatic cystic neoplasms.

Key Highlights

  • CA19.9 levels ≥37 U/mL are considered a relative indication for surgery.
  • Elevated CA19.9 levels are defined as a worrisome feature in IPMN management.
  • The role of CA19.9 in IPMN diagnosis is controversial due to biological heterogeneity.

Guideline-Based Recommendations

Diagnosis

  • Routine assessment of serum CA19.9 during diagnostic workup for IPMN.

Management

  • Consider surgical intervention for patients with elevated CA19.9 levels.

Monitoring & Follow-up

  • Monitor CA19.9 levels in patients with IPMN to assess risk of progression.

Risks

  • Current recommendations are based on retrospective studies, which may introduce selection bias.

Patient & Prescribing Data

Adult patients diagnosed with IPMN who are candidates for surgical resection.

CA19.9 levels can aid in identifying patients at risk for HGD or IC.

Clinical Best Practices

  • Utilize CA19.9 levels as part of a comprehensive diagnostic approach for IPMN.
  • Consider the biological variability of IPMN when interpreting CA19.9 results.

Related Resources & Content

Original Source(s)

Serum CA19.9 for Detecting High-Grade Dysplasia and Invasive Carcinoma in Patients With Intraductal Papillary

  • by Charlotte A. Leseman, Alessandro M. Bonomi, Job Schuitema, Stefano Granieri, Margaret Sällberg Chen, Ajay V. Maker, Zeeshan Ateeb, Laura D. Wood, Rogier P. Voermans, Giovanni Marchegiani, Marco Del Chiaro, Johannes C. F. Ket, Anne Marie Lennon, Marc G. Besselink, Global Evidence-Based Guidelines for the Management of Pancreatic Cystic Neoplasms Group

  • June 26, 2026

Related Content

ESMO Breast Cancer 2026 Highlights: TRAK-ER

Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.

  • June 26, 2026

  • 1 min
Adrenal tumor microenvironment: hormone–immune crosstalk, molecular heterogeneity, and immunotherapeutic opportunities

Troponin for surveillance of immune checkpoint inhibitor–associated myocarditis and post-therapy cardiovascular risk stratification: a systematic review and meta-analysis